Objectives: A clear temporal relationship between myocarditis and pericarditis after COVID-19 vaccination has led to the belief that the vaccine may act as a trigger for these cardiologic complications. The aim of this systematic review is to explore the incidence, clinical presentation, management, and association between them. Methods: We conducted a systematic literature search on Cochrane, MEDLINE, and EMBASE as per guidelines of PRISMA (Preferred Reporting Items for Systematic Reviews). A total of 41 case reports and case series describing 97 patients, and 5 original articles describing 15,585,309 participants were selected as part of this review. Results: Of the 97 reported cases describing vaccine-associated myocarditis/pericarditis, 67 (69%) patients received Pfizer-BioNTech and 25 (25.7%) received Moderna. The mean onset of symptoms after vaccine administration was 3.8 ± 4.5 days with three-quarters developing symptoms after the second dose. Chest pain (n = 88, 90%) and fever (n = 33, 34%) were the most common presenting complaints. Out of 97, 80 (82.5%) patients recovered while 4 (4.1%) patients expired. The pooled incidence of myocarditis and pericarditis extrapolated from original studies is 0.001% and 0.0004%, respectively. In the original studies, nearly all the cases of myocarditis and pericarditis were mild. Chest pain and fever were the most common presenting symptoms. Conclusion: Myocarditis and pericarditis after the COVID-19 vaccine have been reported more in young adult males and are most likely to occur after the second dose of mRNA vaccines. The presentation is mild and the majority of the patients recover either completely or partially.
Objectives: A clear temporal relationship between myocarditis and pericarditis after COVID-19 vaccination has led to the belief that the vaccine may act as a trigger for these cardiologic complications. The aim of this systematic review is to explore the incidence, clinical presentation, management, and association between them. Methods: We conducted a systematic literature search on Cochrane, MEDLINE, and EMBASE as per guidelines of PRISMA (Preferred Reporting Items for Systematic Reviews). A total of 41 case reports and case series describing 97 patients, and 5 original articles describing 15,585,309 participants were selected as part of this review. Results: Of the 97 reported cases describing vaccine-associated myocarditis/pericarditis, 67 (69%) patients received Pfizer-BioNTech and 25 (25.7%) received Moderna. The mean onset of symptoms after vaccine administration was 3.8 ± 4.5 days with three-quarters developing symptoms after the second dose. Chest pain (n = 88, 90%) and fever (n = 33, 34%) were the most common presenting complaints. Out of 97, 80 (82.5%) patients recovered while 4 (4.1%) patients expired. The pooled incidence of myocarditis and pericarditis extrapolated from original studies is 0.001% and 0.0004%, respectively. In the original studies, nearly all the cases of myocarditis and pericarditis were mild. Chest pain and fever were the most common presenting symptoms. Conclusion: Myocarditis and pericarditis after the COVID-19 vaccine have been reported more in young adult males and are most likely to occur after the second dose of mRNA vaccines. The presentation is mild and the majority of the patients recover either completely or partially.
Authors: Tien Dung Nguyen; Gerhard Mall; Julian Georg Westphal; Oliver Weingärtner; Sven Möbius-Winkler; Paul Christian Schulze Journal: ESC Heart Fail Date: 2021-09-18
Authors: George A Diaz; Guilford T Parsons; Sara K Gering; Audrey R Meier; Ian V Hutchinson; Ari Robicsek Journal: JAMA Date: 2021-09-28 Impact factor: 56.272
Authors: Peter Ehrlich; Karin Klingel; Susanne Ohlmann-Knafo; Sebastian Hüttinger; Nitin Sood; Dirk Pickuth; Michael Kindermann Journal: Clin Res Cardiol Date: 2021-09-06 Impact factor: 5.460
Authors: Guy Witberg; Noam Barda; Sara Hoss; Ilan Richter; Maya Wiessman; Yaron Aviv; Tzlil Grinberg; Oren Auster; Noa Dagan; Ran D Balicer; Ran Kornowski Journal: N Engl J Med Date: 2021-10-06 Impact factor: 91.245
Authors: Han W Kim; Elizabeth R Jenista; David C Wendell; Clerio F Azevedo; Michael J Campbell; Stephen N Darty; Michele A Parker; Raymond J Kim Journal: JAMA Cardiol Date: 2021-10-01 Impact factor: 30.154
Authors: Jairo Aldana-Bitar; Noah R Ramirez; Allan S Jaffe; Venkat S Manubolu; Dhiran Verghese; Luay Hussein; Lauren R Anderson; Matthew J Budoff; Ronald P Karlsberg Journal: Cardiol Res Date: 2022-08-15